Literature DB >> 19449079

Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[ 18F]FACBC) with PET in renal carcinoma.

David M Schuster1, Jonathon A Nye, Peter T Nieh, John R Votaw, Raghuveer K Halkar, Muta M Issa, Weiping Yu, Julio Sepulveda, Wanzhen Zeng, Andrew Young, Mark M Goodman.   

Abstract

PURPOSE: Assessment of renal masses with conventional imaging may be challenging. Anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC) is a synthetic L: -leucine analog with relatively little renal excretion. The present study examines anti-[(18)F]FACBC positron emission tomography uptake in patients with renal masses. PROCEDURES: Six patients with seven renal lesions were imaged dynamically for 2 h after injection of 10-10.9 mCi (370-403 MBq) anti-[(18)F]FACBC. Lesions were evaluated qualitatively and quantitatively and correlated with histology.
RESULTS: Four clear cell and one Rosai-Dorfman lesion were hypo/isointense to normal cortex; two papillary lesions in the same patient were hyperintense. Mean SUV(max) +/- SD at 30 min was 2.8 +/- 0.24 for clear cell carcinomas and 4.5 +/- 1.7 for papillary cell lesions. Mean SUV(max)/SUV(mean) ratios +/- SD of lesion to normal cortex at 30 min was 1.15 +/- 0.19 for the clear cell carcinomas and 2.3 +/- 0.84 for papillary cell.
CONCLUSIONS: In this small patient sample, relative amino acid transport compared with renal cortex is elevated in renal papillary cell carcinoma but not in clear cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19449079     DOI: 10.1007/s11307-009-0220-5

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  15 in total

1.  A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer.

Authors:  Shuntaro Oka; Ryota Hattori; Fumie Kurosaki; Masahito Toyama; Larry A Williams; Weiping Yu; John R Votaw; Yasunori Yoshida; Mark M Goodman; Osamu Ito
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

2.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Authors:  David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 3.  Radiologic assessment of renal masses: implications for patient care.

Authors:  A J Davidson; D S Hartman; P L Choyke; B J Wagner
Journal:  Radiology       Date:  1997-02       Impact factor: 11.105

4.  Synthesis of syn- and anti-1-amino-3-[18F]fluoromethyl-cyclobutane-1-carboxylic acid (FMACBC), potential PET ligands for tumor detection.

Authors:  Laurent Martarello; Jonathan McConathy; Vernon M Camp; Eugene J Malveaux; Nicholas E Simpson; Chiab P Simpson; Jeffrey J Olson; Geoffrey D Bowers; Mark M Goodman
Journal:  J Med Chem       Date:  2002-05-23       Impact factor: 7.446

5.  Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors.

Authors:  T M Shoup; J Olson; J M Hoffman; J Votaw; D Eshima; L Eshima; V M Camp; M Stabin; D Votaw; M M Goodman
Journal:  J Nucl Med       Date:  1999-02       Impact factor: 10.057

Review 6.  Renal cell carcinoma: imaging and therapy.

Authors:  Damien M Bolton; Peter Wong; Nathan Lawrentschuk
Journal:  Curr Opin Urol       Date:  2007-09       Impact factor: 2.309

7.  Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging.

Authors:  Alexander Kutikov; Lindsay K Fossett; Parvati Ramchandani; John E Tomaszewski; Evan S Siegelman; Marc P Banner; Keith N Van Arsdalen; Alan J Wein; S Bruce Malkowicz
Journal:  Urology       Date:  2006-10       Impact factor: 2.649

8.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

9.  Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis.

Authors:  Jonathan McConathy; Ronald J Voll; Weiping Yu; Ronald J Crowe; Mark M Goodman
Journal:  Appl Radiat Isot       Date:  2003-06       Impact factor: 1.513

10.  Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans.

Authors:  Jonathon A Nye; David M Schuster; Weiping Yu; Vernon M Camp; Mark M Goodman; John R Votaw
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

View more
  17 in total

Review 1.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

Review 2.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 3.  Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.

Authors:  Vidhya Karivedu; Amit L Jain; Thomas J Eluvathingal; Abhinav Sidana
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

Review 4.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

5.  [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0.

Authors:  Cristina Nanni; Lucia Zanoni; Tore Bach-Gansmo; Heikki Minn; Frode Willoch; Trond Velde Bogsrud; Ephraim Parent Edward; Bital Savir-Baruch; Eugene Teoh; Fenton Ingram; Stefano Fanti; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-11       Impact factor: 9.236

6.  Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti; Shuntaro Oka; Hiroyuki Okudaira; Yusuke Inoue; Jens Sörensen; Rikard Owenius; Peter Choyke; Baris Turkbey; Trond V Bogsrud; Tore Bach-Gansmo; Raghuveer K Halkar; Jonathon A Nye; Oluwaseun A Odewole; Bital Savir-Baruch; Mark M Goodman
Journal:  J Nucl Med       Date:  2014-11-13       Impact factor: 10.057

Review 7.  The next generation of positron emission tomography radiopharmaceuticals in oncology.

Authors:  Samuel L Rice; Celeste A Roney; Pierre Daumar; Jason S Lewis
Journal:  Semin Nucl Med       Date:  2011-07       Impact factor: 4.446

Review 8.  Molecular imaging of the kidneys.

Authors:  Zsolt Szabo; Nada Alachkar; Jinsong Xia; William B Mathews; Hamid Rabb
Journal:  Semin Nucl Med       Date:  2011-01       Impact factor: 4.446

Review 9.  Nuclear imaging of renal tumours: a step towards improved risk stratification.

Authors:  Michael A Gorin; Steven P Rowe; Mohamad E Allaf
Journal:  Nat Rev Urol       Date:  2015-06-09       Impact factor: 14.432

10.  Potential Biomarker of L-type Amino Acid Transporter 1 in Breast Cancer Progression.

Authors:  Zhongxing Liang; Heidi T Cho; Larry Williams; Aizhi Zhu; Ke Liang; Ke Huang; Hui Wu; Chunsu Jiang; Samuel Hong; Ronald Crowe; Mark M Goodman; Hyunsuk Shim
Journal:  Nucl Med Mol Imaging       Date:  2010-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.